ArticleMedicine2026
Arthroscopic meniscal repair versus partial meniscectomy for middle-aged patients with meniscal tears and type 2 diabetes mellitus: A retrospective study on mid-to-long-term outcomes and prognostic factors.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The meniscus plays a critical role in maintaining knee joint stability, absorbing shock, and distributing load-bearing stress. Middle-aged individuals are prone to meniscal tears due to degenerative changes, while type 2 diabetes mellitus (T2DM), a prevalent chronic metabolic disorder, may impair cartilage healing and postoperative recovery, potentially compromising surgical outcomes. However, comparative evidence regarding arthroscopic meniscal repair versus partial meniscectomy in this specific population remains limited. This retrospective cohort study included 122 middle-aged patients with T2DM who underwent arthroscopic treatment for meniscal tears at our center between January 2023 and May 2024. Patients were divided into a repair group (n = 62) and a resection group (n = 60) based on the surgical procedure. Clinical outcomes within 12 months postoperatively were compared, including knee function (Lysholm and International Knee Documentation Committee scores), pain relief (Visual Analog Scale score), complication rate, and magnetic resonance imaging-based imaging findings. Multivariate logistic regression analysis was performed to identify independent predictors of functional recovery. Baseline characteristics were comparable between groups (all P > .05). At both 6 and 12 months postoperatively, the repair group showed significantly better Lysholm and International Knee Documentation Committee scores compared to the resection group (P < .001), along with consistently lower Visual Analog Scale scores (P < .01). Magnetic resonance imaging follow-up revealed a lower rate of cartilage degeneration in the repair group (Outerbridge grade ≥ 2: 16.1% vs 30.0%, P = .048), and the meniscal healing rate reached 85.5%. Complication rates were similar between groups (9.7% vs 11.7%, P = .71). Multivariate analysis identified surgical approach (repair: odds ratio [OR] = 1.92, P = .016), diabetes duration >10 years (OR = 1.78, P = .022), and preoperative glycated hemoglobin >7.5% (OR = 1.66, P = .031) as independent predictors of functional outcome. In middle-aged patients with T2DM and meniscal tears, arthroscopic meniscal repair offers superior outcomes in terms of functional recovery, pain relief, and cartilage preservation compared to partial meniscectomy, with comparable safety profiles. Patients with better glycemic control and shorter diabetes duration are more likely to benefit, supporting the preference for tissue-preserving strategies when feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.